Could a breast cancer drug help fight liposarcoma?

NCT ID NCT02846987

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called abemaciclib in 33 people with dedifferentiated liposarcoma, a rare soft tissue cancer that has spread or cannot be removed by surgery. The drug aims to slow tumor growth or shrink it by at least a quarter. Abemaciclib is not yet approved for this cancer, but has shown promise in other cancers like breast and lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abemaciclib (a targeted cancer drug)
What this could lead to: If it works, this could offer a new treatment option for people with dedifferentiated liposarcoma that has spread or come back.
What could go wrong: This is an early Phase 2 trial with only 33 people. Abemaciclib has not been tested in liposarcoma before, so it may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma liposarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEDIFFERENTIATED LIPOSARCOMA SARCOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.